Loncipoetin alfa (NuPIAO) vs Pegmolesatide (HS-20039)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline
Loncipoetin alfa (NuPIAO)
Marketed by Shenyang Sunshine Pharmaceutical
NCT05211167 · Phase 3 · status unknown
This is a randomized, active-controlled Phase 3 trial with an adequately sized enrollment comparing the study drug against a standard recombinant erythropoietin, using change in hemoglobin, the measure that defines the anemia being treated, as its primary endpoint. However, the trial was not blinded, and results have not been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Reported efficacy
hemoglobin concentration (25th-32nd week): Reached its pre-set primary endpoint (3SBio 2023 annual report; trial completed January 2024); no figures were given. (met)
Result source: NCT05211167
Pegmolesatide (HS-20039)
Marketed by Hansoh Pharmaceutical Group
NCT03902691 · Phase 3 · completed
This randomized, double-blind trial compared pegmolesatide directly against an active comparator, epoetin alfa, rather than placebo. Its prespecified non-inferiority comparison on hemoglobin change was met, with the between-group difference confidence interval falling entirely within the specified margin.
Next expected readout: December 2026 · NCT06946394 (registry estimate)
Reported efficacy
The mean change from the baseline hemoglobin level to the mean level during the evaluation period (Week 17-24): Mean Hb change from baseline: pegmolesatide +19.2 g/L vs epoetin alfa +15.4 g/L; between-group difference 3.8 g/L (95% CI 0.7-6.9), noninferiority margin -10 g/L (met)
Result source: NCT03903809
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Loncipoetin alfa (NuPIAO) | Pegmolesatide (HS-20039) |
|---|---|---|
| Kidney composite outcome | —Not reported | —Not posted · NCT03902691 |
| UACR, % change | —Not reported | —Not posted · NCT03902691 |
| eGFR slope | —Not reported | —Not posted · NCT03902691 |
| Haemoglobin, change | —Not reported | 0.1 vs -0.2avs epoetin alfaNCT03902691 |
Kidney composite outcome
- Loncipoetin alfa (NuPIAO)
- —Not reported
- Pegmolesatide (HS-20039)
- —Not posted · NCT03902691
UACR, % change
- Loncipoetin alfa (NuPIAO)
- —Not reported
- Pegmolesatide (HS-20039)
- —Not posted · NCT03902691
eGFR slope
- Loncipoetin alfa (NuPIAO)
- —Not reported
- Pegmolesatide (HS-20039)
- —Not posted · NCT03902691
Haemoglobin, change
- Loncipoetin alfa (NuPIAO)
- —Not reported
- Pegmolesatide (HS-20039)
- 0.1 vs -0.2avs epoetin alfaNCT03902691
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pegmolesatide (HS-20039)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Loncipoetin alfa (NuPIAO)'s landscape · Pegmolesatide (HS-20039)'s landscape